At the news
? NEUTRALIMPACT 3/10 425 filed Sep 16, 2026 at 17:25 ET
Medtronic CFO Thierry Piton, in a Morgan Stanley conference fireside chat, reiterated the strategic rationale for separating MiniMed, citing its B2C model, lower margins, and higher R&D spend relative to the rest of the portfolio. He noted MiniMed's strong post-IPO stock performance and accelerating innovation cycle, and confirmed the second stage of the exchange offer launched yesterday. No new financial data, revised deal terms, or opposition were disclosed.
- CFO stated MiniMed's R&D spend as a proportion of revenue is about double the rest of Medtronic's portfolio.
- CFO confirmed the second part of the MiniMed exchange offer launched yesterday (September 15, 2026).
- CFO noted MiniMed's Q4 and Q1 numbers were 'great' and 'even better' respectively, with product launches occurring earlier than expected.
- CFO reiterated strategic rationale: focus Medtronic capital on Cardiovascular, MedSurg, and Neuroscience for better returns.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access